InvestDashboard.com



Conatus Pharmaceuticals Inc. (CNAT)



$1.45
52 Week Low
$8.36
2017-04-28 15:47:04 MDT
$8.05
52 Week High

Basic Info

Healthcare
Sector
Biotechnology
Industry
Nasdaq
Stock Exchange
United States
Country

Market Cap: $199,940,000Micro Cap (Less than $200M)
Analyst Recommendation:1.7Analysts say: Buy+. (1=Strong Buy, 5=Strong Sell)
Beta: 2.78 Higher Volatility Stock (beta over 1). Stock will go up more when the market goes up, and go down more when the market goes down. Beta of 1 means stock would match the S&P 500 Index.

Fundamentals

ForwardPE: 28.3
5 Yr Est Growth: 38.00%
Yield: 0.00%
PEG-Y Ratio: 0.74
Excellent Growth Value at a Reasonable Price! Company's growth plus yield is greater than or equal to the PE Ratio. PEGY less than 1 is Excellent!

Technicals

% Above 50 DayMA: 50.90%
% Above 200 DayMA: 114.36%
CNAT Performance 52 Weeks: 156.46%
S&P 500 Performance 52 Weeks: 12.50%
Uptrend is still intact: CNAT is above both 50 and 200 day Moving Averages. There is hope because 50 Day MA is still above 200 Day MA. Stock is closer to 52 Week High than 52 Week Low.
CNAT outperforming S&P 500 by 143.96% the last 52 Weeks. CNAT is close to 52 week high.

Profile


More Valuation

Price To Book: 9.04
OK Value. Low Price to Book means better value. A P/B value of 5 or less is great.
EV to EBITDA: -4.08
Unknown EV to EBITDA ratio

More Info

Field Value Average Comments
% Held By Insiders26.83% 17.28%Held by greater than average Insiders. Insiders can sway stock price. Watch insider buying and selling.
% Held By Institutions34.40% 62.07%Institutional percentage lower than average. Institutions may not have conviction in stock. Or is this a chance for institutions to invest more and boost price?
Short % Of Float5.61% 07.02% Shorted percentage less than average percent. Is stock loved? Do traders and investors believe in the stock?
Debt to Equity0.05 1.08 More Conservative Financing. Each industry has different Debt/Equity standard. Higher than 1 means company is taking on more leverage.
Profit Margin %N/A-00.18%Unknown.
Operating Margin %-3.00%-05.28% Operating Margin greater than average percent. Good.
Return on Equity %-105.57%-08.79% Return on Equity less than average percent. Stock can do better than this?
Return on Assets %-30.55%-01.29% Return on Assets less than average percent. Stock can do better than this?
Revenue Per Employee $31,962.00 $883,096.70 Less than average Revenue Per Employee. This stock (or industry) might not be as efficient as others? Each industry might have a different standard.
Price to Cash 2.84 5.52 Lower than average Price to Cash. Meaning that the company has a higher percentage of cash as a percent of price. Cash can be good to cushion company during hard times, and as a potential source for buyouts or investments. However, some activists want the cash to be used by a company to buy its own stock, or to increase their dividend, or to invest the money.
CPEGY Ratio 0.46 2.26 Less than than average CPEGY Ratio. Ideally, a CPEGY should be less than 1 or less than 1.5. CPEGY is the PEG Ratio but incorporating the yield and subtracting Cash Per Share.

Quick Thoughts

PROS:
  1. Analysts like this stock: 1.7 (1=Strong Buy, 5=Strong Sell)

  2. Excellent PEGY (less than 1): 0.74

  3. Good 5 Yr Est Growth: 38.00%

  4. Stock is Above Short Term 50DMA: 50.90%

  5. Stock is Above Long Term 200DMA: 114.36%

  6. Stock is closer to 52 week high.
  7. Stock outperforming S&P 500 over last 52 weeks: 143.96%

  8. Price to Cash Ratio (2.84) is less than average. Good. Company has more cash as percentage of price than other companies.

  9. Shorted less than average: 5.61%

  10. Debt To Equity is lower than 1: 0.05

CONS:
  1. High Forward PE: 28.3

  2. Operating Margin is negative: -3.00%

  3. Return on Equity is negative: -105.57%

  4. Return on Assets is negative: -30.55%


Headlines


Stock Chart


InvestDashboard.com CNAT: Conatus Pharmaceuticals Inc.

This page updated Thu Feb 1 22:00:01 MST 2018.